On October 9, Celltrion, Inc. announced it had received the nod from the FDA on the latest aflibercept biosimilar, Eydenzelt (aflibercept-boav). This Eylea biosimilar is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Celltrion will join a heavily competitive field when it does … Continue reading Celltrion Receives FDA Approval for Its Aflibercept Biosimilar